{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:00:01Z","timestamp":1767985201723,"version":"3.49.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold>YZJ-4729 is a novel G protein-biased \u03bc-opioid receptor agonist for the treatment of acute pain in adult patients who require intravenous opioid analgesic therapy. The aim of this study was to assess the pharmacokinetics, metabolite profiling, safety and tolerability of YZJ-4729 in healthy Chinese subjects following the single intravenous doses ranged from 0.2\u00a0mg to 6\u00a0mg.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>This single-center, randomized, double-blind, placebo-controlled clinical study was conducted in 54 healthy male and female Chinese subjects after single ascending doses of YZJ-4729 tartrate (0.2, 0.5, 1.5, 3, 4.5, and 6\u00a0mg). Subjects in each cohort were assigned randomly to receive a single intravenous dose of YZJ-4729 tartrate injection or placebo at a ratio of 4:1. Pharmacokinetic characteristics, metabolite profiling, safety and tolerability profiles of the study drug were evaluated.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>Overall, YZJ-4729 was safe and well tolerated in healthy Chinese subjects. The study drug reached peak plasma concentrations nearly at the end of the infusion. After administration, YZJ-4729 was eliminated rapidly with a terminal elimination half-life of 0.862\u20132.50\u00a0h, and excreted little in human excreta. The maximum drug concentration and area under the plasma concentration-time curve increased with dose escalation across the entire dose range. YZJ-4729 experienced extensive metabolism in human body. A total of 19 metabolites were identified and the characteristic metabolic pathways involved hydroxylation, ketone formation, N-dealkylation and glucuronide conjugation. Metabolite M10 was the most abundant circulating metabolite, and represented over 10% of total drug-related systemic exposure. Further PK and safety evaluation of M10 was necessary.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>The clinical study results laid a foundation for the further clinical studies of YZJ-4729 in patients.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>http:\/\/www.chinadrugtrials.org.cn<\/jats:ext-link>, identifier CTR20222574.<\/jats:p>","DOI":"10.3389\/fphar.2023.1295319","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T04:31:26Z","timestamp":1704774686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, metabolite profiling, safety and tolerability of YZJ-4729 tartrate, a novel G protein-biased \u03bc-opioid receptor agonist, in healthy Chinese subjects"],"prefix":"10.3389","volume":"14","author":[{"given":"Yufeng","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaye","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minlu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(99)03313-9","article-title":"Acute pain","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"eaav0320","DOI":"10.1126\/scisignal.aav0320","article-title":"Biased ligands at opioid receptors: current status and future directions","volume":"14","author":"Che","year":"2021","journal-title":"Sci. Signal."},{"key":"B4","unstructured":"Guidance for estimating the maximum recommended starting dose (MRSD) of drugs in the first clinical trial of healthy adult volunteers2012"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.3390\/molecules25184257","article-title":"Biased opioid ligands","volume":"25","author":"Faouzi","year":"2020","journal-title":"Molecules"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1209131","DOI":"10.3389\/fphar.2023.1209131","article-title":"Efficacy of opioids for traumatic pain in the emergency department: a systematic review and Bayesian network meta-analysis","volume":"14","author":"Fu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0033-1351138","article-title":"Postoperative pain control","volume":"26","author":"Garimella","year":"2013","journal-title":"Clin. Colon Rectal Surg."},{"key":"B8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2231-4040.72250","article-title":"Clinical aspects of acute post-operative pain management and its assessment","volume":"1","author":"Gupta","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/clpt.1981.56","article-title":"Determination of mean valproic acid serum level by assay of a single pooled sample","volume":"29","author":"Hamilton","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature14886","article-title":"Structural insights into \u00b5-opioid receptor activation","volume":"524","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/pst.326","article-title":"Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion","volume":"8","author":"Hummel","year":"2009","journal-title":"Pharm. Stat."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S0140-6736(06)68700-X","article-title":"Persistent postsurgical pain: risk factors and prevention","volume":"367","author":"Kehlet","year":"2006","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.cps.2019.11.001","article-title":"Pain: pathways and physiology","volume":"47","author":"Lee","year":"2020","journal-title":"Clin. Plast. Surg."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1163976","DOI":"10.3389\/fphar.2023.1163976","article-title":"Variation in adverse drug events of opioids in the United States","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/j354v16n04_02","article-title":"Clinical pharmacokinetics of morphine","volume":"16","author":"Lugo","year":"2002","journal-title":"J. Pain and Palliat. Care Pharmacother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s40265-020-01414-9","article-title":"Oliceridine: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11916-018-0690-8","article-title":"New advances in acute postoperative pain management","volume":"22","author":"Mitra","year":"2018","journal-title":"Curr. Pain Headache Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.2174\/1568026620999201027224229","article-title":"The G protein signal-biased compound TRV130; structures, its site of action and clinical studies","volume":"20","author":"Miyano","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/rapm-2019-100714","article-title":"Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain","volume":"45","author":"Ottoboni","year":"2019","journal-title":"Reg. Anesth. Pain Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update","volume":"6","author":"Pathan","year":"2012","journal-title":"Br. J. Pain"},{"key":"B23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/art.37739","article-title":"Central pain mechanisms in the rheumatic diseases: future directions","volume":"65","author":"Phillips","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2147\/JPR.S303186","article-title":"Chronic pain: what does it mean? A review on the use of the term chronic pain in clinical practice","volume":"14","author":"Raffaeli","year":"2021","journal-title":"J. Pain Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","article-title":"The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises","volume":"161","author":"Raja","year":"2020","journal-title":"Pain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/EJA.0000000000000366","article-title":"Current issues in postoperative pain management","volume":"33","author":"Rawal","year":"2016","journal-title":"Eur. J. Anaesthesiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1002\/bjs.11477","article-title":"Acute postoperative pain management","volume":"107","author":"Small","year":"2020","journal-title":"Br. J. Surg."},{"key":"B28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jcph.207","article-title":"First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"54","author":"Soergel","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"840270","DOI":"10.3389\/fpsyt.2022.840270","article-title":"The influence of preoperative mood and treatment expectations on early postsurgical acute pain after a total knee replacement","volume":"13","author":"Stuhlreyer","year":"2022","journal-title":"Front. Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/j.pain.0000000000000160","article-title":"A classification of chronic pain for ICD-11","volume":"156","author":"Treede","year":"2015","journal-title":"Pain"},{"key":"B31","first-page":"11","article-title":"Recent advances in postoperative pain management","volume":"83","author":"Vadivelu","year":"2010","journal-title":"Yale J. Biol. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1517\/14740338.6.2.125","article-title":"Naloxone treatment in opioid addiction: the risks and benefits","volume":"6","author":"Van Drop","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2017.07.009","article-title":"How ligands illuminate GPCR molecular pharmacology","volume":"170","author":"Wacher","year":"2017","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1219866","DOI":"10.3389\/fphar.2023.1219866","article-title":"Chemical characterization and metabolic profiling of Xiao-Er-An-Shen Decoction by UPLC-QTOF\/MS","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1218380","DOI":"10.3389\/fphar.2023.1218380","article-title":"Subacute toxicity evaluations of LPM3480392 in rats, a full \u00b5-opioid receptor biased agonist","volume":"14","author":"Ye","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"10959","DOI":"10.1021\/acs.jafc.7b04265","article-title":"UHPLC-Q-TOF-MS\/MS method based on four-step strategy for metabolism study of fisetin in vitro and in vivo","volume":"65","author":"Zhang","year":"2017","journal-title":"J. Agric. Food Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1295319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:26:43Z","timestamp":1731004003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1295319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":35,"alternative-id":["10.3389\/fphar.2023.1295319"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1295319","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"article-number":"1295319"}}